Takeda Pharmaceutical Reports Decline in Revenue and Profit
Takeda Pharmaceutical Company Limited reported a decline in revenue and profits for the six-month period ending September 30, 2025. Revenue fell by 6.9% to JPY 2,219.5 billion, while operating profit dropped 27.7% to JPY 253.6 billion. Net profit decreased by 39.9% to JPY 112.5 billion. The company revised its full-year forecast, expecting a slight decline in core operating profit and EPS. Despite challenges, Takeda is focused on strategic priorities, including new product launches and cost-saving measures, with a broadly flat revenue outlook.
Takeda Pharmaceutical Company Limited is a global pharmaceutical company based in Japan, focusing on research and development in areas such as oncology, gastroenterology, and neuroscience. It is listed on multiple stock exchanges, including Tokyo and Nagoya.
In its latest earnings report for the six-month period ending September 30, 2025, Takeda reported a decline in revenue and profits compared to the same period last year. The company faced challenges such as generic erosion in its neuroscience segment and unfavorable foreign exchange rates.
Key financial highlights include a 6.9% decrease in revenue to JPY 2,219.5 billion and a 27.7% drop in operating profit to JPY 253.6 billion. The net profit for the period decreased by 39.9% to JPY 112.5 billion. The company also revised its full-year forecast, expecting a slight decline in core operating profit and EPS.
Despite the current challenges, Takeda remains focused on its strategic priorities, including new product launches and cost-saving measures. The management anticipates a broadly flat revenue outlook and aims to navigate through the current market conditions with strategic adjustments.
